Citi Moleculars Llp - Company Profile

It is a chemicals limited liability partnership based in Kolkata, West Bengal, India, established in 2020.
2020 Kolkata, West Bengal, India Active
Last Updated:
Access Report
About Citi Moleculars Llp

Citi Moleculars Llp, a active limited liability partnership, was established on 31 August 2020 in Kolkata, West Bengal, India. Engaging in chemicals and chemical products within the chemicals sector, it holds LLPIN: AAT-6016. Registered under ROC Roc Kolkata. It has total obligation of contribution of ₹0.40 M.

Its leadership includes Arvind Kumar Verma (Designated Partner), Meena Dhawan (Designated Partner), Tarishe Dhawan (Designated Partner). Past directors included Anunay Dhawan. Its latest date of accounts and solvency statement 31 March 2025. It is based at 63/1A,Sarat Bose Road Lansdowne Market, Police Station:Bhowani, Pore, Kolkata, West Bengal, 700025.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    AAT-6016

  • Incorporation Date

    31 August 2020

  • Total Obligation of Contribution

    ₹0.40 M

  • ROC Code

    Roc Kolkata

  • Company Status

    Active

Key Metrics
  • Obligation of Contribution ₹ 0.40 M
  • Company Age 5 Year, 6 Months
  • Last Filing with ROC 31 Mar 2025
Company report

Citi Moleculars Llp

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Citi Moleculars Llp — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Citi Moleculars Llp?
Current Designated Partners
Name Designation Appointment Date Status
Arvind Kumar Verma Designated Partner 31 Aug 2020 Current
Meena Dhawan Designated Partner 31 Aug 2020 Current
Tarishe Dhawan Designated Partner 03 Jul 2025 Current
Veer Arjun Dhawan Designated Partner 31 Aug 2020 Current
Past Designated Partners
Name Designation Cessation Status
Pramod Abcsdd Designated Partner 03 Jul 2025 Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Citi Moleculars Llp.

Enhance accessibility to Citi Moleculars Llp's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.

Citi Moleculars Llp revenue growth over time
Citi Moleculars Llp profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
*******
*******
*******
*******
*******
Revenue from Operations
*******
*******
*******
*******
*******
*******
Total Assets
*******
*******
*******
*******
*******
*******
Profit or Loss
*******
*******
*******
*******
*******
*******
Net Worth
*******
*******
*******
*******
*******
*******
EBITDA
*******
*******
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Citi Moleculars Llp?

Unlock access to Citi Moleculars Llp's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

How Many Employees Work at Citi Moleculars Llp?

Unlock and access historical data on people associated with Citi Moleculars Llp, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Citi Moleculars Llp, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Citi Moleculars Llp's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Citi Moleculars Llp
Recent Activity within the Organization
  • Director Appointment

    Progress on Tarishe Dhawan was appointed as a Designated Partner was appointed as a Designated Partner on 03 Jul 2025 & has been associated with this company since 8 months 4 days . was documented.

  • Annual General Meeting

    The activity Citi Moleculars Llp last Annual general meeting of members was held on 31 Mar 2025 as per latest MCA records. was completed.

  • Statement of Assets & Liabilities

    The activity Citi Moleculars Llp has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Kolkata. was completed.

  • Director Appointment

    The activity Arvind Kumar Verma was appointed as a Designated Partner was appointed as a Designated Partner on 31 Aug 2020 & has been associated with this company since 5 years 6 months . was completed.

  • Director Appointment

    The activity Meena Dhawan was appointed as a Designated Partner was appointed as a Designated Partner on 31 Aug 2020 & has been associated with this company since 5 years 6 months . was completed.

  • Director Appointment

    Progress on Veer Arjun Dhawan was appointed as a Designated Partner was appointed as a Designated Partner on 31 Aug 2020 & has been associated with this company since 5 years 6 months . was documented.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the LLPIN of Citi Moleculars Llp?

The LLPIN of Citi Moleculars Llp is AAT-6016.

Where is Citi Moleculars Llp headquartered?

Citi Moleculars Llp is headquartered at 63/1A,Sarat Bose Road Lansdowne Market, Police Station:Bhowani, Pore, Kolkata, West Bengal, 700025.

When was Citi Moleculars Llp incorporated?

Citi Moleculars Llp was incorporated on 31 August 2020.

Who are the current directors of Citi Moleculars Llp?

The current directors of Citi Moleculars Llp are

What is the primary industry of Citi Moleculars Llp?

The primary industry of Citi Moleculars Llp is Chemicals.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available